Role of angiogenesis in the progression and treatment of prostate cancer.
Choy
M
M
Laboratory of Vascular Hematology, Division of Hematology/Medical Oncology, Weill Medical College of Cornell University, New York, New York, USA.
Rafii
S
S
D000728:Androgens / Q000502:physiology; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D016207:Cytokines / Q000502:physiology; D018450:Disease Progression; D016228:Endothelial Growth Factors / Q000502:physiology; D006801:Humans; D008222:Lymphokines / Q000502:physiology; D008297:Male; D009389:Neovascularization, Pathologic; D011471:Prostatic Neoplasms / Q000098:blood supply / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000728:Androgens; D020533:Angiogenesis Inhibitors; D016207:Cytokines; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors